RASSF1 Antibody

1. Tissues from patients with serous and non-serous EOC showed significantly higher promoter methylation of EGFL7 and RASSF1 compared to benign cases. PMID: 29778234
2. Transcriptome assay unclosed that RASSF1A promoted IL-6 expression in A375 cells, which in turn activate JAK2/STAT3 signaling. PMID: 30074127
3. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy. PMID: 27698403
4. Low RASSF1A expression is associated with gastric cancer. PMID: 30106448
5. methylation of BRCA1, RASSF1A and GSTP1 was found in 58.23 %, 74.68 % and 59.49 % of tumor tissues and 51.90 %, 63.29 % and 35.44 % of corresponding adjacent tissues, respectively PMID: 30049201
6. Our study established that RASSF1A hypermethylation might have a potential value in the clinical diagnosis of colorectal cancer PMID: 30082160
7. Effect of decitabine pretreatment on sensitivity of bladder cancer cells towards chemotherapeutic drugs was also studied. Decitabine treatment leads to restoration of RASSF1A, activation of hippo pathway followed by decreased expression of its oncogenic downstream targets (CTGF & CYR61). PMID: 29368096
8. the use of RASSF1A promoter methylation could distinguish ovarian cancer and low malignant potential tumors. -RASSF1A promoter methylation may not be correlated with the clinical features and the survival of ovarian cancer patients. PMID: 29130987
9. the methylation positive rates of SHOX2 with RASSF1A in stage III were both higher than the other stages of lung cancer PMID: 28325362
10. Tested if RASSF1A polymorphisms associated with ovarian cancer and with tumor grade and stage. Five tagging single nucleotide polymorphisms (SNPs) (rs4688728G>T, rs72932987C>T, rs1989839C>T, rs2073497A>C, and rs2236947A>C) were evaluated. The CT genotype of rs1989839 was associated with the patients with ovarian cancer (P=0.001), and was significantly correlated with tumor grade and stage (P=0.008). PMID: 29670073
11. No significant differences were presented in DNA methylation levels of RASSF1A and ATM between the sporadic breast cancer cases and the healthy controls. PMID: 29562656
12. High Promoter Methylation of RASSF1A gene is associated with Breast Cancer. PMID: 29480000
13. Hypermethylation of RASSF1 gene is associated with neuroendocrine tumors. PMID: 29851970
14. The present work proved that there was a higher frequency of RASSF1A methylation and a decrease in its serum level in patients with ovarian cancer compared to controls as well as in the high-grade tumor patients compared to low grade ones and also in advanced ovarian tumor stage compared to early stages. PMID: 29098560
15. Promoter methylation of RASSF1A can influence sensitivity to oxaliplatin-based chemotherapy, which can be used to predict outcomes for patients with stage II and III Colorectal Cancer PMID: 29128865
16. The meta-analysis indicates a role of the RASSF1A promoter hypermethylation from peripheral blood in testicular germ cell tumors. PMID: 28871003
17. RASSF1A is a tumour suppressor gene epigenetically dysregulated in NET. Aberrant methylation of RASSF1A has been reported in various tumours, but this is the first report of RASSF1A hypermethylation in TETs. PMID: 28838380
18. Study shows that recombinant human bone morphogenetic protein-2 activates hippo signaling through RASSF1 in esophageal cancer cells PMID: 27230238
19. There were significant associations between RASSF1A promoter hypermethylation and Oral Cancer risk.RASSF1A promoter hypermethylation exerted higher frequency in the Tongue Tumor than other site tumor in mouth. PMID: 29538221
20. RASSF1A is expressed in differentiating stem cells. PMID: 29382819
21. Hypermethylation of RASSF1A gene is associated with Colon Cancer. PMID: 26671036
22. Data show that silencing DNA methyltransferase 1 (DNMT1) increased expression of tumor suppressor genes, RASSF1A and DAPK, in esophageal squamous cell carcinoma (ESCC) cells and ESCC xenograft in nude mice. PMID: 27286455
23. Describe a novel interaction between Rheb and the tumor suppressor RASSF1A. This interaction may allow coordinate upregulation of Hippo while TOR is suppressed to modulate the balance of apoptosis and autophagy in lung tumor cells. PMID: 27034171
24. Gestational age-dependent increase of hypermethylated RASSF1A; the fetal specific epigenetic marker in maternal plasma was demonstrated, in an Indian study group of normal pregnant women. PMID: 27165812
25. the RASSF1 gene polymorphism influences molecular carcinogenesis and clinic pathological features of hepatocellular carcinoma within the Egyptian population PMID: 26921475
26. We report for the first time that RASSF1A promoter methylation provides significant prognostic information in high-grade serous ovarian cancer patients. PMID: 28206954
27. The main finding of this study was the significant association between RASSF1A promoter methylation and increased EC risk. PMID: 28669560
28. Data suggest that the overexpression of DNMT3B4 may play an important role in human kidney tumorigenesis through chromosomal instability and methylation of RASSF1A. PMID: 28160561
29. Methylation status of the RASSF1A gene promoter was strongly related to melanoma susceptibility but no significant difference was found between RASSF1A gene promoter methylation and the prognosis and clinical-pathological features of melanoma. PMID: 28207831
30. Our results suggest a multifactorial role of RASSF1A in suppression of liver carcinogenesis PMID: 26980762
31. rs1989839C/T is an important predictor of osteosarcoma risk and outcome. The CT genotype of rs1989839 is highly related to elevated risk of osteosarcoma. Furthermore, rs1989839C/T is also associated with the Enneking stage of osteosarcoma and risk of lung metastasis. One of the other 4 SNPs, rs2236947A/C, shows a borderline significance in predicting osteosarcoma risk. PMID: 27880743
32. For the first time, we performed analysis of DNA methylation in SMARCB1/INI1-deficient sinonasal carcinomas, reporting on significantly higher methylation of RASSF1 gene in this neoplasm. PMID: 28069272
33. High methylation in the RASSF1A promoter region is associated with lung cancer. PMID: 27716889
34. GSTP1, APC and RASSF1 gene methylation in prostate cancer samples: comparative analysis of MS-HRM method and Infinium HumanMethylation450 BeadChip beadchiparray diagnostic value PMID: 28026816
35. Compared with adjacent normal tissues, the methylation frequencies of WIF-1, RASSF1A, and CDH13 genes were significantly higher but the mRNA levels of these 3 genes were significantly lower in EC tissues. The survival rates of patients with WIF-1, RASSF1A, and CDH13 methylations were significantly lower than those of patients without methylation PMID: 27506957
36. The presence of higher RASSF1A methylation levels in fine-needle aspiration cytology specimens of nodular goitre may be useful in the assessment of oncological risk. PMID: 26457492
37. this meta-analysis demonstrated that RASSF1A promoter methylation is significantly associated with increased risk of renal cell cancer PMID: 27173228
38. Overexpression of RASSF1A downregulated the cyclin D1. PMID: 26750098
39. Results show that RASSF1A is involved in colorectal tumorigenesis. Its promotor region is bind to miR-181b stimulating its expression. PMID: 26935905
40. The meta-analysis suggested that there was a significant association between aberrant RASSF1A methylation and head and neck squamous cell carcinoma. PMID: 26857374
41. The present meta.analysis provides convincing evidence that the promoter methylation ratio of RASSF1A and p16 is associated with clinicopathological features in lung cancers, and could be used as effective biomarkers in early diagnosis in lung cancers. PMID: 27072261
42. Loss of RASSF1A is associated with gastric cancer. PMID: 26735582
43. Different genetic mechanisms seem to contribute to RASSF1 deregulation in this setting, but RASSF1 methylation does not seem to substantially affect RASSF1 isoforms expression. PMID: 26754001
44. RASSF1C gene is not involved in Clear-cell renal cell carcinoma (ccRCC)progression and we propose that the measurements of RASSF1A mRNA levels in paired tumor-normal kidney tissue could serve as a new prognostic factor in ccRCC PMID: 26648328
45. Results indicate that hypermethylation of tumor suppressor protein RASSF1A and docking protein 1 (DOK1) contributes to hepatocarcinogenesis and is associated to clinicopathological characteristics. PMID: 27078152
46. Data indicate tumor suppressors TP73, RASSF1A, MLH1 and BRCA1 as possible biomarkers to distinguish Pleomorphic invasive lobular cancer (pleomorphic ILC} from classic ILC and infiltrative ductal cancer (IDC). PMID: 26392358
47. Interaction between HPV infection and RASSF1A promoter methylation is associated with the development of cervical cancers. PMID: 26320446
48. Hypermethylation of RASSF1A gene promoter is associated with esophageal squamous cell carcinoma. PMID: 25886188
49. RASSF1A promotes the translocation of cytosolic PRMT5 to microtubules.PRMT5 co-localizes with RASSF1A on stabilized microtubules. PMID: 26482848
50. Tumor-adjacent tissues showed higher methylation status of RASSF1A, HIN-1 and MGMT promoters. PMID: 26370119

显示更多

收起更多

HGNC: 9882

OMIM: 605082

KEGG: hsa:11186

STRING: 9606.ENSP00000349547

UniGene: Hs.476270